Adult haemophagocytic syndrome M Ramos-Casals, P Brito-Zerón, A López-Guillermo, MA Khamashta, ... The Lancet 383 (9927), 1503-1516, 2014 | 1400 | 2014 |
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review G Ruiz-Irastorza, M Ramos-Casals, P Brito-Zeron, MA Khamashta Annals of the rheumatic diseases 69 (01), 20-28, 2010 | 1168 | 2010 |
The 2019 American College of Rheumatology/European league against rheumatism classification criteria for IgG4‐related disease ZS Wallace, RP Naden, S Chari, H Choi, E Della‐Torre, JF Dicaire, ... Arthritis & Rheumatology 72 (1), 7-19, 2020 | 868 | 2020 |
Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases M Ramos-Casals, P Brito-Zerón, S Muñoz, N Soria, D Galiana, ... Medicine 86 (4), 242-251, 2007 | 855 | 2007 |
Sjögren syndrome P Brito-Zerón, C Baldini, H Bootsma, SJ Bowman, R Jonsson, X Mariette, ... Nature reviews Disease primers 2 (1), 1-20, 2016 | 772 | 2016 |
EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies M Ramos-Casals, P Brito-Zerón, S Bombardieri, H Bootsma, S De Vita, ... Annals of the rheumatic diseases 79 (1), 3-18, 2020 | 473 | 2020 |
Primary Sjögren syndrome M Ramos-Casals, P Brito-Zerón, A Sisó-Almirall, X Bosch Bmj 344, 2012 | 395 | 2012 |
The clinical spectrum of IgG4-related disease P Brito-Zerón, M Ramos-Casals, X Bosch, JH Stone Autoimmunity reviews 13 (12), 1203-1210, 2014 | 352 | 2014 |
Autoimmune diseases induced by TNF-targeted therapies M Ramos-Casals, P Brito-Zerón, MJ Soto, MJ Cuadrado, MA Khamashta Best practice & research Clinical rheumatology 22 (5), 847-861, 2008 | 349 | 2008 |
Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases R Pérez-Alvarez, C Díaz-Lagares, F García-Hernández, L Lopez-Roses, ... Medicine 90 (6), 359-371, 2011 | 337 | 2011 |
EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide R Seror, SJ Bowman, P Brito-Zeron, E Theander, H Bootsma, A Tzioufas, ... RMD open 1 (1), e000022, 2015 | 333 | 2015 |
Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases R Perez-Alvarez, M Perez-de-Lis, C Diaz-Lagares, JM Pego-Reigosa, ... Seminars in arthritis and rheumatism 41 (2), 256-264, 2011 | 333 | 2011 |
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient … R Seror, H Bootsma, A Saraux, SJ Bowman, E Theander, JG Brun, ... Annals of the rheumatic diseases 75 (2), 382-389, 2016 | 331 | 2016 |
Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements M Ramos-Casals, P Brito-Zerón, R Seror, H Bootsma, SJ Bowman, ... Rheumatology 54 (12), 2230-2238, 2015 | 315 | 2015 |
The clinical spectrum of autoimmune congenital heart block P Brito-Zerón, PM Izmirly, M Ramos-Casals, JP Buyon, MA Khamashta Nature Reviews Rheumatology 11 (5), 301-312, 2015 | 303 | 2015 |
Systemic and organ-specific immune-related manifestations of COVID-19 M Ramos-Casals, P Brito-Zerón, X Mariette Nature Reviews Rheumatology 17 (6), 315-332, 2021 | 273 | 2021 |
Systemic involvement in primary Sjögren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry) M Ramos-Casals, P Brito-Zeron, R Solans, MT Camps, A Casanovas, ... Rheumatology 53 (2), 321-331, 2014 | 271 | 2014 |
Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients M Ramos-Casals, N Nardi, M Lagrutta, P Brito-Zerón, A Bové, G Delgado, ... Medicine 85 (2), 95-104, 2006 | 255 | 2006 |
Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome M Ramos-Casals, P Brito-Zeron, J Yague, M Akasbi, R Bautista, M Ruano, ... Rheumatology 44 (1), 89-94, 2005 | 226 | 2005 |
Topical and systemic medications for the treatment of primary Sjögren's syndrome M Ramos-Casals, P Brito-Zeron, A Siso-Almirall, X Bosch, AG Tzioufas Nature Reviews Rheumatology 8 (7), 399-411, 2012 | 225 | 2012 |